Search

Displaying results 971 - 980 of 4262 in total
  1. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.

  2. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12.

  3. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma. … Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking its enzymatic activity, thereby interfering with DNA synthesis.

  5. Drug

    Levosimendan

    go.drugbank.com/drugs/DB00922
    ApprovedInvestigationalWithdrawn

    Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

  6. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  7. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]

  8. Drug

    Calcium gluconate

    go.drugbank.com/drugs/DB11126
    ApprovedInvestigationalVet approved

    It can also be taken by mouth but is not recommended by injection into a muscle.

  9. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen